Clinical trial
A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
NCT02188160 is registered in ClinicalTrials.gov with Kala Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2014
- Completion date
- March 31, 2015
- Enrollment
- 150 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.